Conversation with The Cancer LetterFree NCI Director Monica Bertagnolli has breast cancer“I have more motivation to get up every morning to keep doing what I do” December 14, 2022Vol.48 No.45By Paul Goldberg and Matthew Bin Han Ong
NCI’s Bertagnolli & ARPA-H’s Wegrzyn have been plotting to make the most of their strengths and differences December 09, 2022Vol.48 No.44By Matthew Bin Han Ong
Guest Editorial PAMN: How cancer centers develop ways to communicate the value of research December 09, 2022Vol.48 No.44By Heidi Findlay
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
Guest Editorial A “new normal” for NCI-sponsored clinical trials is long overdue November 18, 2022Vol.48 No.42By Richard L. Schilsky
A brief report sets forth a “new normal,” lets NCI start to streamline clinical trials November 11, 2022Vol.48 No.41By Paul Goldberg
Conversation with The Cancer Letter NCI’s Doroshow: “These recommendations are something that we can implement right away” November 11, 2022Vol.48 No.41By Paul Goldberg
NCI Bertagnolli sets out eight “core principles” for NCI: “We’ve got to be nimbler, faster” November 11, 2022Vol.48 No.41
